FKB327, an Adalimumab Biosimilar, Versus the Reference Product: Results of a Randomized, Phase III, Double-Blind Study, and Its Open-Label Extension
Arthritis Research & Therapy
doi 10.1186/s13075-019-2046-0
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Springer Science and Business Media LLC